Antiviral activity ofBifidobacterium adolescentisSPM1605 against Coxsackievirus B3
Authors:
Open Access
- 4 July 2014
- journal article
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 28 (4) , 681-688
Abstract
Bifidobacteria are considered one of the most beneficial probiotics and have been widely studied for their effects against specific pathogens. The present study investigated the antiviral activity of probiotics isolated from Koreans against Coxsackievirus B3 (CVB3). The effect of probiotic isolates against CVB3 was measured by the plaque assay and cellular toxicity of bifidobacteria in HeLa cells was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Among 13 probiotic isolates, 3 Bifidobacterium adolescentis, 2 Bifidobacterium longum and 1 Bifidobacterium pseudocatenulatum had an antiviral effect against CVB3, while the others did not show such effect. B. adolescentis SPM1605 showed the greatest inhibitory properties against CVB3. When the threshold cycle (CT) values for the treated B. adolescentis SPM1605 samples were compared to the results for the non-treated samples, it was shown that the amplified viral sequences from the CVB3 had their copy number lowered by B. adolescentis SPM1605. Moreover, the gene expression in infected HeLa cells was also inhibited by 50%. The results suggest that B. adolescentis SPM1605 suppresses CVB3 and could be used as an alternative therapy against infectious diseases caused by coxsackieviruses.Keywords
This publication has 31 references indexed in Scilit:
- Antiviral activity of Bifidobacterium adolescentisSPM1005-A on human papillomavirus type 16BMC Medicine, 2012
- Development of a Gene Therapy Method for Cervical Cancer Using Attenuated Coxsackievirus B3 as a Vector SystemJournal of Bacteriology and Virology, 2011
- Interferon-inducible antiviral effectorsNature Reviews Immunology, 2008
- The human fatty acid synthase: A new therapeutic target for coxsackievirus B3-induced diseases?Antiviral Research, 2007
- Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice AnymoreClinical Infectious Diseases, 2007
- Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trialVaccine, 2006
- Development of Peptide Antibody against Coxsackievirus B3 VP2Journal of Bacteriology and Virology, 2006
- A Small Interfering RNA Targeting Coxsackievirus B3 Protects Permissive HeLa Cells from Viral ChallengeJournal of Virology, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Treatment of viral myocarditis with focus on captoprilThe American Journal of Cardiology, 1996